profit from every $100 of sales.
$0$100
CRISPR Therapeutics
$42.62-6.84% today
-18.3% in 1 year
1-year low $42.621-year high $61.89
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What CRISPR Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $436,000 in 2022 to $0 in 2025, with -$582 million of profit last year.
SalesProfit
CRISPR Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| CRISPR Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads CRISPR Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 370 | 35 | 0 | |
| -110 | 240 | -86 | -213 | |
| -673 | -223 | -467 | -665 | |
| -649 | -203 | -447 | -645 | |
| -650 | -154 | -366 | -582 | |
| -8.36 | -1.94 | -4.34 | -6.47 | |
| -25,186.7% | 64.8% | -244.8% | – | |
| -154,394.7% | -60.1% | -1,333.0% | – | |
| -149,122.7% | -41.5% | -1,046.4% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,243 | 2,230 | 2,242 | 2,265 |
| Cash | 212 | 389 | 298 | 348 |
| Total debt | 244 | 239 | 224 | 207 |
| Total liabilities | 368 | 347 | 310 | 343 |
| 1,875 | 1,883 | 1,932 | 1,922 | |
| 78 | 79 | 84 | 90 | |
| -25.1% | -8.3% | -17.1% | -24.7% | |
| -34.7% | -8.2% | -19.0% | -30.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -496 | -260 | -143 | -345 | |
| 37 | 12 | 2 | 26 | |
| -533 | -272 | -145 | -371 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 98 | 81 | 87 | 72 |
Valuation
- –
- –
- –
- 2.8×
- 118.1×
- –
- –
- -3.5%
- -8.9%
- 0.0%
Profitability
- -244.8%
- -1,333.0%
- -1,046.4%
- -12,305.4%
- -21.1%
- -13.1%
- -30.9%
- -20.9%
- -21.2%
- 6,596.0%
Growth
- +796.0%
- –
- −139.1%
- –
- +4.3%
Financial health
- -0.2×
- 0.43
- 28.9%
- –
- 17.96
- 17.96
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 957
Bottom 22%of 986
What analysts expect
- Average price target
- $63.00
- Range
- $33.00 – $82.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -1.28 | -1.18 | −8.2% |
| Feb 12, 2026 | -1.37 | -1.15 | −19.1% |
| Nov 10, 2025 | -1.17 | -1.26 | +7.1% |
| Aug 4, 2025 | -1.29 | -1.47 | +12.2% |
| May 6, 2025 | -1.58 | -1.27 | −24.4% |
| Feb 11, 2025 | -0.44 | -1.15 | +61.7% |
| Nov 5, 2024 | -1.01 | -1.33 | +24.1% |
| Aug 5, 2024 | -1.49 | -1.37 | −8.8% |
News
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreYahoo Finance · Oct 24, 2026Where Will CRISPR Therapeutics Stock Be in 2030?Yahoo Finance · Oct 18, 2026Gene editing stocks fall after Anthropic’s CRISPR-like discoverySeeking Alpha · Sep 23, 20263 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026Yahoo Finance · Sep 20, 2026Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?Yahoo Finance · Sep 18, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
39No pass
Philip Fisher
31No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
35No pass
Terry Smith
30No pass
Questions about CRISPR Therapeutics
Is CRISPR Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CRISPR Therapeutics AI analysis
What does CRISPR Therapeutics do?
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. It is in Biotechnology, based in Zug, Switzerland.
Does CRISPR Therapeutics pay a dividend?
No. CRISPR Therapeutics does not pay a dividend at the moment.
Is CRISPR Therapeutics stock halal?
Questionable. CRISPR Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has CRISPR Therapeutics stock done over the past year?
Down 18.3% over the past twelve months, to $42.62. It traded between $42.62 and $61.89 and is 31.1% below its high.
Who are CRISPR Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with CRISPR Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.